# Phibro Animal Health Corp: overview

PAHC · Nasdaq · CIK 1069899 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/pahc.md) · [Financials](/companies/pahc/financials.md) · [Filings](/companies/pahc/filings.md) · [Insiders](/companies/pahc/insiders.md)

Latest reported revenue: [$396.7m](/filings/0001104659-26-101493.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Aug 26, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-101493).

## Last eight quarters

| Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [260](/filings/0001104659-25-107001.md) | [309](/filings/0001104659-26-010317.md) | [348](/filings/0001104659-26-056280.md) | [379 d](/filings/0001104659-26-101493.md) | [364](/filings/0001104659-25-107001.md) | [374](/filings/0001104659-26-010317.md) | [384](/filings/0001104659-26-056280.md) | [397 d](/filings/0001104659-26-101493.md) |
| Gross margin | % | [32.1%](/filings/0001104659-25-107001.md) | [32.9%](/filings/0001104659-26-010317.md) | [30.1%](/filings/0001104659-26-056280.md) | [29.0% d](/filings/0001104659-26-101493.md) | [32.9%](/filings/0001104659-25-107001.md) | [35.5%](/filings/0001104659-26-010317.md) | [32.8%](/filings/0001104659-26-056280.md) | [33.9% d](/filings/0001104659-26-101493.md) |
| Operating margin | % | [6.8%](/filings/0001104659-25-107001.md) | [8.3%](/filings/0001104659-26-010317.md) | [9.6%](/filings/0001104659-26-056280.md) | [8.9% d](/filings/0001104659-26-101493.md) | [14.1%](/filings/0001104659-25-107001.md) | [13.5%](/filings/0001104659-26-010317.md) | [11.6%](/filings/0001104659-26-056280.md) | [12.1% d](/filings/0001104659-26-101493.md) |
| Net margin | % | [2.7%](/filings/0001104659-25-107001.md) | [1.0%](/filings/0001104659-26-010317.md) | [6.0%](/filings/0001104659-26-056280.md) | [4.5% d](/filings/0001104659-26-101493.md) | [7.3%](/filings/0001104659-25-107001.md) | [7.3%](/filings/0001104659-26-010317.md) | [6.3%](/filings/0001104659-26-056280.md) | [5.5% d](/filings/0001104659-26-101493.md) |
| Diluted EPS | $ per share | [0.17](/filings/0001104659-25-107001.md) | [0.08](/filings/0001104659-26-010317.md) | [0.51](/filings/0001104659-26-056280.md) | not reported | [0.65](/filings/0001104659-25-107001.md) | [0.67](/filings/0001104659-26-010317.md) | [0.59](/filings/0001104659-26-056280.md) | not reported |
| Free cash flow | $m | [3.0](/filings/0001104659-25-107001.md) | [(4.7) d](/filings/0001104659-26-010317.md) | [35.4 d](/filings/0001104659-26-056280.md) | [8.1 d](/filings/0001104659-26-101493.md) | [(4.5)](/filings/0001104659-25-107001.md) | [8.3 d](/filings/0001104659-26-010317.md) | [0.9 d](/filings/0001104659-26-056280.md) | [5.2 d](/filings/0001104659-26-101493.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [942](/filings/0001558370-24-012517.md) | [978](/filings/0001558370-25-011776.md) | [1,018](/filings/0001104659-26-101493.md) | [1,296](/filings/0001104659-26-101493.md) | [1,518](/filings/0001104659-26-101493.md) |
| Gross margin | % | [30.3%](/filings/0001558370-24-012517.md) | [30.5%](/filings/0001558370-25-011776.md) | [30.8%](/filings/0001104659-26-101493.md) | [30.9%](/filings/0001104659-26-101493.md) | [33.8%](/filings/0001104659-26-101493.md) |
| Operating margin | % | [8.4%](/filings/0001558370-24-012517.md) | [7.3%](/filings/0001558370-25-011776.md) | [5.2%](/filings/0001104659-26-101493.md) | [8.5%](/filings/0001104659-26-101493.md) | [12.8%](/filings/0001104659-26-101493.md) |
| Net margin | % | [5.2%](/filings/0001558370-24-012517.md) | [3.3%](/filings/0001558370-25-011776.md) | [0.2%](/filings/0001104659-26-101493.md) | [3.7%](/filings/0001104659-26-101493.md) | [6.6%](/filings/0001104659-26-101493.md) |
| Diluted EPS | $ per share | [1.21](/filings/0001558370-24-012517.md) | [0.81](/filings/0001558370-25-011776.md) | [0.06](/filings/0001104659-26-101493.md) | [1.19](/filings/0001104659-26-101493.md) | [2.43](/filings/0001104659-26-101493.md) |
| Free cash flow | $m | [(5.4)](/filings/0001558370-24-012517.md) | [(38.5)](/filings/0001558370-25-011776.md) | [46.4](/filings/0001104659-26-101493.md) | [41.8](/filings/0001104659-26-101493.md) | [9.9](/filings/0001104659-26-101493.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pahc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $101.1m | 3,219,040 |  | Reduced −34,808 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $99.2m | 3,160,281 |  | Added +987,155 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $32.6m | 1,038,382 |  | Added +88,349 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $29.4m | 936,701 |  | Added +880,882 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $29.0m | 923,318 |  | Added +32,035 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $20.6m | 657,350 |  | Added +52,702 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $16.7m | 531,087 |  | Added +23,235 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $16.0m | 508,486 |  | Added +18,144 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $15.1m | 480,500 |  | Reduced −96,235 |
| [CastleKnight Management LP](/funds/1835751.md) | 2026-06-30 | $14.5m | 461,322 |  | Added +385,427 |

## Recent filings

[All 692 filings](/companies/pahc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-18 | 20:10 ET | [DEF 14A](/filings/0001104659-26-108939.md) | Proxy statement, period 2026-11-03 | 0001104659-26-108939 |
| 2026-08-26 | 20:30 ET | [8-K](/filings/0001104659-26-101531.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-101531 |
| 2026-08-26 | 20:14 ET | [10-K](/filings/0001104659-26-101493.md) | Annual report, period 2026-06-30 | 0001104659-26-101493 |
| 2026-07-28 | 20:16 ET | [8-K](/filings/0001104659-26-087544.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-087544 |
| 2026-06-26 | 21:07 ET | [8-K](/filings/0001104659-26-078323.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-078323 |
| 2026-05-22 | 20:24 ET | [SCHEDULE 13D/A](/filings/0001104659-26-065746.md) | Ownership report, active investor, amended | 0001104659-26-065746 |
| 2026-05-06 | 20:39 ET | [8-K](/filings/0001104659-26-056316.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-056316 |
| 2026-05-06 | 20:25 ET | [10-Q](/filings/0001104659-26-056280.md) | Quarterly report, period 2026-03-31 | 0001104659-26-056280 |
| 2026-05-05 | 20:47 ET | [8-K](/filings/0001104659-26-055699.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-055699 |
| 2026-04-30 | 20:16 ET | [8-K](/filings/0001104659-26-052956.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001104659-26-052956 |

## Latest annual report

[Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001104659-26-101493.md), filed Aug 26, 2026.

## Forecast league

Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/715a0c84-a313-45c9-ac2d-baac6b3d3851)

## About the filer

- CIK: 1069899
- Tickers: PAHC
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.